

KING & SPALDING LLP
1185 Avenue of the Americas
New York, New York 10036-2601
Telephone: (212) 556-2100
Facsimile: (212) 556-2222
Scott Davidson

Special Counsel to the Debtors and Debtors in Possessions

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., et al.,¹

Debtors.

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**TWENTY-SEVENTH MONTHLY FEE STATEMENT OF KING & SPALDING LLP
FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE
DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM
NOVEMBER 1, 2021 THROUGH NOVEMBER 30, 2021**

Name of Applicant	King & Spalding LLP
Applicant's Role in Case	Special Counsel to Purdue Pharma L.P., et al.
Date Order of Employment Signed	November 25, 2019 [Docket No. 543] August 18, 2021 [Docket No. 3596]
Period for Which Compensation and Reimbursement is Sought	November 1, 2021 through November 30, 2021

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Summary of Total Fees and Expenses Requested	
Total Compensation Requested in this Statement	\$181,110.96 (80% of \$226,388.70)
Total Reimbursement Requested in this Statement	\$0.00
Total Compensation and Reimbursement Requested in this Statement	\$181,110.96
This is a(n): <input checked="" type="checkbox"/> Monthly Application <input type="checkbox"/> Interim Application <input type="checkbox"/> Final Application	

Pursuant to sections 327, 330, and 331 of chapter 11 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), Rule 2016-1 of the Local Bankruptcy Rules for the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), the *Order Authorizing the Retention and Employment of King & Spalding LLP as Special Counsel for the Debtors Nunc Pro Tunc to the Petition Date*, dated November 25, 2019 [Docket No. 543] (the “**Initial Retention Order**”), the *Order Authorizing Application of Debtors for Authority to Supplement Retention and Employment of King & Spalding LLP as Special Counsel to the Debtors Nunc Pro Tunc To July 7, 2021*, dated August 18, 2021 [Docket No. 3596] (the “**Supplemental Retention Order**,” and with the Initial Retention Order, the “**Retention Orders**”) and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”), King & Spalding LLP (“**K&S**”), special counsel to the above-captioned debtors and

debtors in possession (collectively, the “**Debtors**”), submits this *Monthly Statement of Services Rendered and Expenses Incurred for the Period from November 1, 2021 Through November 30, 2021* (this “**Fee Statement**”).² By this Fee Statement, and after taking into account certain voluntary discounts and reductions,³ K&S seeks (i) compensation in the amount of \$181,110.96, which is equal to 80% of the total amount of reasonable compensation for actual, necessary legal services that K&S incurred in connection with such services during the Fee Period (*i.e.*, \$226,388.70) and (ii) payment of \$0.00, for the actual, necessary expenses that K&S incurred in connection with such services during the Fee Period.

Itemization of Services Rendered and Disbursements Incurred

1. Attached hereto as **Exhibit A** is a chart of the number of hours expended and fees incurred (on an aggregate basis) by K&S partners, counsel, associates, discovery counsel, privilege review attorneys, and paraprofessionals during the Fee Period with respect to each of the project categories K&S established in accordance with its internal billing procedures. As reflected in **Exhibit A**, K&S incurred \$226,388.70 in fees during the Fee Period. Pursuant to this Fee Statement, K&S seeks reimbursement for 80% of such fees, totaling \$181,110.96.

2. Attached hereto as **Exhibit B** is a chart of K&S professionals and paraprofessionals, including the standard hourly rate for each attorney and paraprofessional who rendered services to the Debtors in connection with these chapter 11 cases during the Fee Period and the title, hourly

² The period from November 1, 2021 through and including November 30, 2021 is referred to herein as the “**Fee Period**.”

³ K&S agreed as a courtesy to the Debtors to bill at approximately 90% of its hourly rates in effect when the services are rendered. Additionally, K&S agreed to offer additional discounts, including on a sliding scale on fees exceeding certain amounts.

rate, aggregate hours worked and the amount of fees earned by each professional. The blended hourly billing rate of attorneys for all services provided during the Fee Period is \$517.22.⁴

3. Attached hereto as **Exhibit C** is a chart of expenses that K&S incurred or disbursed in the amount of \$0.00 in connection with providing professional services to the Debtors during the Fee Period.

4. Attached hereto as **Exhibit D** are the time records of K&S for the Fee Period organized by project category with a daily time log describing the time spent by each attorney and other professional during the Fee Period as well as an itemization of expenses.

Notice

5. K&S will provide notice of this Fee Statement in accordance with the Interim Compensation Order. K&S submits that no other or further notice be given.

WHEREFORE, K&S, in connection with services rendered on behalf of the Debtors during the Fee Period, respectfully requests (i) compensation in the amount of \$181,110.96, which is equal to 80% of the total amount of reasonable compensation for actual, necessary legal services that K&S incurred in connection with such services during the Fee Period (*i.e.*, \$226,388.70) and (ii) payment of \$0.00 for the actual, necessary expenses that K&S incurred in connection with such services during the Fee Period.

⁴ The blended hourly rate of \$517.22 for attorneys is derived by dividing the total fees for attorneys of \$226,388.70 by the total hours of 437.7. There was no paraprofessional time incurred during the Fee Period.

Dated: December 8, 2021
New York, New York

KING & SPALDING LLP

/s/ Scott Davidson

Scott Davidson
1185 Avenue of the Americas
New York, New York 10036-2601
Telephone: (212) 556-2100
Facsimile: (212) 556-2222

*Special Counsel to the Debtors and Debtors in
Possession*

Exhibit A

Fees by Project Category⁵

⁵ The total fees listed in Exhibit A do not reflect additional discounts, as applicable, agreed to with the Debtors.

Project Category	Total Hours	Total Fees
Analysis/Strategy	164.2	\$145,560.22
Document Production (Defense)	244.2	\$57,605.13
Retention and Fee Applications	29.1	\$26,693.50
TOTALS	437.7	\$229,858.85

Exhibit B

Professional & Paraprofessional Fees⁶

⁶ The hourly billing rate and total compensation listed in Exhibit B for each timekeeper do not reflect additional discounts, as applicable, agreed to with the Debtors.

Name of Professional Individual	Position, Year Assumed Position, Prior Relevant Experience, years of Obtaining Relevant License to Practice	Hourly Billing Rate	Total Hours Billed	Total Compensation
Partners				
Jeffrey Bucholtz	Partner; joined K&S 2009; admitted to Washington, D.C.	\$1,195.00	60.5	\$72,297.50
Rose Jones	Partner; joined K&S 2003; admitted to Georgia 2002	\$500.00	26.5	\$13,250.00
Marisa Maleck	Partner; joined K&S 2016; admitted to Maryland 2012, Washington, D.C. 2013	\$965.00	10.8	\$10,422.00
Paul Mezzina	Partner; joined K&S 2020; admitted to California 2009, Washington, D.C. 2011	\$1,015.00	22.4	\$22,736.00
Hap Shashy	Partner; joined K&S 2012; admitted to Florida 1974, New York 1977, Texas 1984, Washington, D.C.	\$1,475.00	28.3	\$41,742.50
John Tucker	Partner; joined K&S 1999; admitted to Kentucky 1995, Georgia 2000	\$500.00	2.2	\$1,100.00
Counsel				
Scott Davidson	Counsel; joined K&S 2009; admitted to New York 1996	\$1,290.00	9.2	\$11,868.00
Associate				
Leia Shermohammed	Associate; joined K&S 2017; admitted to Georgia 2015	\$745.00	19.9	\$14,825.50
Discovery Counsel				
Nicole Bass	Discovery counsel; joined K&S 2010; admitted to Georgia 2010	\$350.00	15.9	\$5,565.00
Kassi Burns	Discovery counsel; joined K&S 2021; admitted to Arkansas 2006	\$350.00	25.1	\$8,785.00

Name of Professional Individual	Position, Year Assumed Position, Prior Relevant Experience, years of Obtaining Relevant License to Practice	Hourly Billing Rate	Total Hours Billed	Total Compensation
Privilege Review Attorneys				
Michael Douglas	Privilege review attorney; joined K&S 2003; admitted to Georgia 1999	\$240.00	7.2	\$1,728.00
Reilly Schreck	Privilege review attorney; joined K&S 2012; admitted to Georgia 2012	\$240.00	2.7	\$648.00
Eric Smedley	Privilege review attorney; joined K&S 2000; admitted to Georgia 1999	\$240.00	9.2	\$2,208.00
David Vandiver	Privilege review attorney; joined K&S 1999; admitted to Georgia 1990	\$240.00	23.4	\$5,616.00
Hao Wang	Privilege review attorney; joined K&S 2016; admitted to Georgia 2017	\$240.00	5.3	\$1,272.00
Austin Gibson	Privilege review attorney; joined K&S 2017; admitted to Georgia 2016	\$240.00	66.8	\$16,032.00
Chris Harris	Privilege review attorney; joined K&S 2007; admitted to Georgia 2006 joined K&S 2007; admitted to Georgia 2006	\$240.00	18.7	\$4,488.00
Kathleen Lynch	Privilege review attorney; joined K&S 2014; admitted to Georgia 2011	\$240.00	83.6	\$20,064.00

Exhibit C

Summary of Actual and Necessary Expenses

Expense Category	Total Expenses
TOTAL	\$0.00

Exhibit D

Detailed Time Records and Expenses

KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:
King & Spalding LLP
P.O. Box 116133
Atlanta, GA 30368-6133

By Wire: SunTrust Bank
ABA: 061 000 104
SWIFT: SNTRUS3A
USD Account: 88003 12475
Account Name: King & Spalding

Purdue Pharma LP
Sent Electronically

Invoice No. 10486454
Invoice Date 12/07/21
Client No. 08714
Matter No. 158001

RE: DOJ Opioid Marketing Investigations
Client Matter Reference: 20190002327

For questions, contact:
Jeffrey Bucholtz (202) 626-2907

For Professional Services Rendered from November 1, 2021 through November 30, 2021:

Fees	\$	105,455.50
Less Courtesy Fee Discount (13.0%)		-13,709.21
Total this Invoice	\$	91,746.29

Payment is Due Upon Receipt

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 2

PROFESSIONAL SERVICES

Date	Timekeeper	Task	Activity	Description	Hours
11/01/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, M. Florence, team regarding DOJ and bankruptcy issues (0.4); review materials regarding DOJ and bankruptcy issues (0.4)	0.8
11/02/21	J Bucholtz	L120	A106	Confer with M. Kesselman, M. Huebner, P. Fitzgerald, M. Florence, J. Bragg, R. Aleali, E. Vonnegut, P. Mezzina, M. Maleck, team regarding DOJ and bankruptcy issues (3.2); review materials regarding DOJ and bankruptcy issues (0.6)	3.8
11/03/21	J Bucholtz	L120	A105	Confer with M. Florence, P. Mezzina, M. Maleck, team regarding DOJ and bankruptcy issues (2.1); review materials regarding DOJ and bankruptcy issues (0.7)	2.8
11/03/21	M Maleck	L120	A105	Conference with J. Bucholtz and P. Mezzina regarding DOJ and bankruptcy issues	0.7
11/03/21	P Mezzina	L120	A105	Conference with J. Bucholtz and M. Maleck regarding bankruptcy and DOJ issues	0.7
11/03/21	P Mezzina	L120	A104	Review and analyze materials regarding bankruptcy and DOJ issues	2.7
11/04/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, J. Bragg, M. Florence, M. Huebner, S. Stefanik, DOJ, team regarding DOJ and bankruptcy issues (2.6); review and edit materials regarding DOJ and bankruptcy issues (0.8)	3.4
11/04/21	P Mezzina	L120	A104	Review and analyze materials regarding bankruptcy and DOJ issues	3.2
11/05/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, J. Bragg, M. Florence, S. Stefanik, team regarding DOJ and bankruptcy issues (1.1); review materials regarding DOJ and bankruptcy issues (0.7)	1.8
11/06/21	J Bucholtz	L120	A107	Confer with M. Huebner, E. Vonnegut, M. Florence, team regarding DOJ and bankruptcy issues	0.5
11/06/21	M Maleck	L120	A104	Analyze materials regarding DOJ and bankruptcy issues	1.1
11/06/21	P Mezzina	L120	A104	Review and analyze materials regarding	2.2

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 3

Date	Timekeeper	Task	Activity	Description	Hours
11/08/21	J Bucholtz	L120	A107	bankruptcy and DOJ issues Confer with M. Huebner, B. Kaminetzky, P. Fitzgerald, M. Florence, team regarding DOJ and bankruptcy issues (0.9); confer with P. Mezzina, M. Maleck regarding DOJ and bankruptcy issues (0.2); review materials regarding DOJ and bankruptcy issues (0.3)	1.4
11/09/21	J Bucholtz	L120	A106	Confer with M. Kesselman, B. Kaminetzky, M. Huebner, P. Fitzgerald, team regarding bankruptcy and DOJ issues (0.6); listen to stay hearing (1.7); review materials regarding bankruptcy and DOJ issues (0.4)	2.7
11/09/21	P Mezzina	L120	A102	Review and analysis concerning bankruptcy and DOJ issues	1.6
11/09/21	P Mezzina	L120	A105	Conference with J. Bucholtz and M. Maleck regarding bankruptcy and DOJ issues	0.5
11/10/21	J Bucholtz	L120	A107	Confer with P. Mezzina, M. Maleck regarding DOJ and bankruptcy issues (0.5); confer with R. Aleali, P. Fitzgerald, J. Bragg, M. Florence, B. Kaminetzky, team regarding DOJ and bankruptcy issues (0.8); review and edit materials regarding DOJ and bankruptcy issues (0.3)	1.6
11/10/21	M Maleck	L120	A104	Analyze DOJ and bankruptcy issues (0.8); meet with P. Mezzina and J. Bucholtz regarding same (0.5)	1.3
11/10/21	P Mezzina	L120	A105	Confer with J. Bucholtz and M. Maleck regarding bankruptcy and DOJ issues	0.5
11/11/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, J. Bragg, M. Florence, R. Aleali, S. Stefanik regarding DOJ and bankruptcy issues (0.8); review and edit materials regarding DOJ and bankruptcy issues (0.8); confer with G. Cardillo, P. Mezzina, M. Maleck regarding DOJ and bankruptcy issues (0.2)	1.8
11/12/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, M. Florence, team regarding DOJ and bankruptcy issues (0.6); review materials regarding DOJ and bankruptcy issues (0.6); confer with P. Mezzina, M. Maleck regarding DOJ and bankruptcy issues (0.2)	1.4

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 4

Date	Timekeeper	Task	Activity	Description	Hours
11/12/21	M Maleck	L120	A104	Review and analyze DOJ and bankruptcy issues	1.5
11/12/21	P Mezzina	L120	A105	Conference with J. Bucholtz and M. Maleck regarding bankruptcy and DOJ issues	1.1
11/12/21	P Mezzina	L120	A104	Review and analyze DOJ and bankruptcy issues	3.9
11/13/21	J Bucholtz	L120	A106	Review and edit materials regarding bankruptcy and DOJ issues (2.4); confer with M. Kesselman, G. Cardillo, H. Coleman, P. Mezzina, M. Maleck regarding bankruptcy and DOJ issues (0.7)	3.1
11/13/21	M Maleck	L120	A104	Review and analysis of DOJ and bankruptcy issues	1.0
11/13/21	P Mezzina	L120	A105	Conference with M. Maleck and J. Bucholtz regarding bankruptcy and DOJ issues	0.8
11/14/21	J Bucholtz	L120	A107	Confer with R. Aleali, P. Fitzgerald, M. Florence, J. Weiner, team regarding DOJ and bankruptcy issues	0.3
11/15/21	J Bucholtz	L120	A106	Confer with M. Kesselman, R. Aleali, M. Huebner, B. Kaminetzky, J. Weiner, C. Robertson, P. Fitzgerald, M. Florence, team regarding DOJ and bankruptcy issues (1.8); review materials regarding DOJ and bankruptcy issues (0.4)	2.2
11/15/21	M Maleck	L120	A105	Review materials regarding DOJ and bankruptcy issues	0.2
11/15/21	P Mezzina	L120	A105	Conference with M. Maleck and S. Lima regarding bankruptcy and DOJ materials	0.2
11/16/21	J Bucholtz	L120	A106	Confer with M. Kesselman, P. Fitzgerald, J. Bragg, M. Florence, R. Aleali, E. Vonnegut, C. Robertson, S. Birnbaum, team regarding DOJ and bankruptcy issues (2.2); review materials regarding DOJ and bankruptcy issues (0.4)	2.6
11/17/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, M. Florence, team regarding DOJ and bankruptcy issues	0.2
11/18/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, M. Florence, J. Bragg, B. Ridgway regarding DOJ and bankruptcy issues	1.2

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 5

Date	Timekeeper	Task	Activity	Description	Hours
11/19/21	J Bucholtz	L120	A107	Confer with M. Florence, P. Fitzgerald, J. Simonelli, team regarding DOJ and bankruptcy issues	0.4
11/21/21	J Bucholtz	L120	A107	Confer with J. Bragg, team regarding DOJ and bankruptcy issues	0.2
11/22/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, J. Bragg, team regarding DOJ and bankruptcy issues (0.5); review materials regarding DOJ and bankruptcy issues (0.2)	0.7
11/23/21	J Bucholtz	L120	A106	Confer with M. Kesselman, M. Huebner, P. Fitzgerald, S. Birnbaum, M. Florence, M. Maleck, team regarding bankruptcy and DOJ issues (1.4); review materials regarding bankruptcy and DOJ issues (0.8)	2.2
11/23/21	M Maleck	L120	A104	Review and analyze DOJ and bankruptcy issues	1.5
11/23/21	P Mezzina	L120	A104	Review and analyze bankruptcy and DOJ materials	1.5
11/24/21	J Bucholtz	L120	A107	Confer with P. Fitzgerald, M. Florence, P. Mezzina, M. Maleck, K. Benedict, team regarding DOJ and bankruptcy issues	0.6
11/24/21	P Mezzina	L120	A104	Review and analyze bankruptcy and DOJ materials	1.5
11/24/21	P Mezzina	L120	A105	Conference with J. Bucholtz and M. Maleck regarding bankruptcy and DOJ issues	1.5
11/25/21	J Bucholtz	L120	A104	Review materials regarding DOJ and bankruptcy issues	0.8
11/26/21	J Bucholtz	L120	A107	Confer with G. Cardillo, P. Fitzgerald, team regarding bankruptcy and DOJ issues (0.3); review materials regarding bankruptcy and DOJ issues (3.4)	3.7
11/26/21	P Mezzina	L120	A104	Review DOJ and bankruptcy issues	0.3
11/27/21	J Bucholtz	L120	A106	Review materials regarding bankruptcy and DOJ issues (2.8); confer with M. Kesselman, B. Kaminetzky, M. Tobak, P. Fitzgerald, H. Coleman, M. Maleck, team regarding bankruptcy and DOJ issues (1.4)	4.2
11/27/21	M Maleck	L120	A104	Review and analyze DOJ and bankruptcy issues	3.5
11/27/21	P Mezzina	L120	A105	Review bankruptcy and DOJ materials	0.2
11/28/21	J Bucholtz	L120	A104	Confer with M. Kesselman, J. Adams,	7.3

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 6

Date	Timekeeper	Task	Activity	Description	Hours
				P. Fitzgerald, M. Huebner, M. Tobak, team regarding bankruptcy and DOJ issues (4.2); review materials regarding bankruptcy and DOJ issues (2.8); confer with J. Bragg, M. Florence, B. McConagha regarding DOJ and bankruptcy issues (0.3)	
11/29/21	J Bucholtz	L120	A106	Confer with M. Kesselman, P. Fitzgerald, M. Florence, DOJ, team regarding DOJ and bankruptcy issues (2.4); review materials regarding DOJ and bankruptcy issues (0.7)	3.1
11/30/21	J Bucholtz	L120	A107	Attend appellate oral argument, confer with J. Adams, P. Fitzgerald, M. Florence, team regarding same (4.5); review and edit materials regarding DOJ and bankruptcy issues (1.2)	5.7
					<hr/> 93.7

TIMEKEEPER SUMMARY

Timekeeper	Status	Hours	Rate	Value
Jeffrey Bucholtz	Partner	60.5	1195.00	72,297.50
Marisa Maleck	Partner	10.8	965.00	10,422.00
Paul Mezzina	Partner	22.4	1015.00	22,736.00
Total		<hr/> 93.7		<hr/> \$105,455.50

08714 Purdue Pharma LP
158001 DOJ Opioid Marketing Investigations
12/07/21

Invoice No. 10486454
Page 7

Task Summary - Fees

Task		Hours	Value
L120	Analysis/Strategy	93.7	91,746.29
	Total Fees	<u>93.7</u>	<u>91,746.29</u>

KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:
King & Spalding LLP
P.O. Box 116133
Atlanta, GA 30368-6133

By Wire: SunTrust Bank
ABA: 061 000 104
SWIFT: SNTRUS3A
USD Account: 88003 12475
Account Name: King & Spalding

Purdue Pharma LP
Sent Electronically

Invoice No. 10486456
Invoice Date 12/07/21
Client No. 08714
Matter No. 090001

RE: Plan Transaction Tax Issues
Client Matter Reference: 20210003141

For questions, contact:
Jeffrey Bucholtz (202) 626-2907

For Professional Services Rendered from November 01, 2021 through November 30, 2021:

Fees	\$	41,742.50
Less Courtesy Fee Discount (13.0%)		-5,426.52
Total this Invoice	\$	36,315.98

Payment is Due Upon Receipt

08714 Purdue Pharma LP
090001 Plan Transaction Tax Issues
12/07/21

Invoice No. 10486456
Page 2

PROFESSIONAL SERVICES

Date	Timekeeper	Task	Activity	Description	Hours
11/01/21	H Shashy	L120	A108	Confer with IRS regarding pre-submission memorandum	0.4
11/02/21	H Shashy	L120	A104	Analysis of tax questions	1.3
11/02/21	H Shashy	L120	A108	Telephone conference with IRS regarding pre-submission memorandum	0.8
11/03/21	H Shashy	L120	A108	Confer with IRS regarding pre-submission memorandum	0.6
11/03/21	H Shashy	L120	A104	Analysis of tax issues (1.3); review of IRS guidance request authorities (1.2)	2.5
11/04/21	H Shashy	L120	A101	Preparation for IRS conference	1.4
11/04/21	H Shashy	L120	A108	Confer with IRS regarding pre-submission memorandum and attachments	0.9
11/04/21	H Shashy	L120	A103	Revision of IRS submissions	0.6
11/05/21	H Shashy	L120	A107	Confer with Davis Polk regarding IRS submissions	0.7
11/05/21	H Shashy	L120	A103	Revision of IRS submissions	0.7
11/05/21	H Shashy	L120	A101	Preparation for IRS conference	1.3
11/08/21	H Shashy	L120	A104	Analysis of tax authorities relevant to IRS guidance request	2.0
11/11/21	H Shashy	L120	A104	Analysis of tax issues	1.8
11/12/21	H Shashy	L120	A104	Analysis of tax authorities	1.8
11/12/21	H Shashy	L120	A107	Confer with Davis Polk regarding IRS submission	0.4
11/17/21	H Shashy	L120	A108	Confer with IRS regarding pre-sub memorandum and related matters (0.9); conference with DPW and NRF regarding IRS pre-submissions matters (0.3)	1.2
11/18/21	H Shashy	L120	A104	Analysis of IRS guidance issues and potential presentation to IRS regarding same	2.2
11/19/21	H Shashy	L120	A104	Analysis of IRS guidance requirements and presentation approach to IRS regarding guidance submission	2.3
11/22/21	H Shashy	L120	A108	Telephone conference with IRS regarding guidance submission	0.7
11/22/21	H Shashy	L120	A104	Analysis of authorities regarding IRS guidance submission	0.9
11/29/21	H Shashy	L120	A104	Analysis regarding tax issues	1.7

08714 Purdue Pharma LP
090001 Plan Transaction Tax Issues
12/07/21

Invoice No. 10486456

Page 3

Date	Timekeeper	Task	Activity	Description	Hours
11/30/21	H Shashy	L120	A107	Confer with Davis Polk regarding IRS guidance submission	0.8
11/30/21	H Shashy	L120	A104	Initial review of Davis Polk analysis of tax issues	1.3
					<hr/> 28.3

TIMEKEEPER SUMMARY

Timekeeper	Status	Hours	Rate	Value
Hap Shashy	Partner	28.3	1475.00	41,742.50
Total		<hr/> 28.3		<hr/> \$41,742.50

08714 Purdue Pharma LP
090001 Plan Transaction Tax Issues
12/07/21

Invoice No. 10486456
Page 4

Task Summary - Fees

Task		Hours	Value
L120	Analysis/Strategy	28.3	36,315.98
	Total Fees	<u>28.3</u>	<u>36,315.98</u>

KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:
King & Spalding LLP
P.O. Box 116133
Atlanta, GA 30368-6133

By Wire: SunTrust Bank
ABA: 061 000 104
SWIFT: SNTRUS3A
USD Account: 88003 12475
Account Name: King & Spalding

Purdue Pharma LP
Sent Electronically

Invoice No.	10486455
Invoice Date	12/07/21
Client No.	08714
Matter No.	240001

RE: Retention And Fee Application
Client Matter Reference: 20190002705

For questions, contact:
Jeffrey Bucholtz (202) 626-2907

For Professional Services Rendered from November 01, 2021 through November 30, 2021:

Fees	\$	26,693.50
Less Courtesy Fee Discount (13.0%)		-3,470.15
Total this Invoice	\$	23,223.35

Payment is Due Upon Receipt

08714 Purdue Pharma LP
240001 Retention And Fee Application
12/07/21

Invoice No. 10486455
Page 2

PROFESSIONAL SERVICES

Date	Timekeeper	Task	Activity	Description	Hours
11/01/21	L Shermohammed	L210	A103	Draft interim fee application	2.1
11/02/21	L Shermohammed	L210	A103	Draft interim fee application	1.7
11/04/21	L Shermohammed	L210	A103	Draft interim fee application	1.1
11/08/21	S Davidson	L120	A104	E-mails to L. Shermohammed regarding upcoming interim fee application (0.4); review budget information (0.3); review relevant monthly fee statements and amounts requested (0.9)	1.6
11/09/21	S Davidson	L120	A104	Review information and e-mail to team regarding budget information (0.5); e-mails with R. Jones regarding budget information (0.3); e-mails with J. Bucholtz and H. Shashy regarding budget information (0.5)	1.3
11/10/21	S Davidson	L120	A104	E-mails with R. Jones regarding Budget matters	0.5
11/10/21	L Shermohammed	L210	A103	Draft sixth interim fee application	0.7
11/11/21	S Davidson	L120	A104	E-mails with H. Shashy and J. Bucholtz regarding budget matters	0.4
11/11/21	L Shermohammed	L210	A103	Draft sixth interim fee application	1.9
11/12/21	S Davidson	L120	A106	Review J. Bucholtz' e-mail with budget information (0.2); compose email to client regarding same (0.3); e-mails with L. Shermohammed regarding interim fee application (0.3).	0.8
11/12/21	L Shermohammed	L210	A103	Draft sixth interim fee application	2.9
11/14/21	L Shermohammed	L210	A103	Draft sixth interim fee application	1.4
11/15/21	S Davidson	L120	A104	Review draft of sixth interim fee application and provide comments (0.9); e-mails with L. Shermohammed, J. Bucholtz and R. Jones regarding additional information for interim fee application (0.5); review final version of interim fee application, make minor revisions and finalize (0.4); coordinate filing and service of sixth interim fee application (0.3); e-mail as filed interim fee application to Fee Examiner (0.1)	2.2
11/15/21	L Shermohammed	L210	A103	Draft and finalize sixth interim fee application	3.2
11/29/21	S Davidson	L120	A104	E-mails with L. Shermohammed regarding monthly fee statement and schedule for next week	0.4

08714 Purdue Pharma LP
240001 Retention And Fee Application
12/07/21

Invoice No. 10486455
Page 3

Date	Timekeeper	Task	Activity	Description	Hours
11/29/21	L Shermohammed	L210	A103	Draft monthly fee application	2.1
11/30/21	S Davidson	L120	A104	E-mails regarding status of monthly fee statement (0.2); review draft of October monthly fee statement (0.4); review exhibits (0.3); revisions to monthly fee statement and finalize for filing (0.5); coordinate filing and service of monthly fee statement (0.3); request LEDES data (0.1); e-mail regarding filing of monthly fee statement and timing of November monthly fee statement (0.2)	2.0
11/30/21	L Shermohammed	L210	A103	Draft and finalize monthly fee application	2.8
					<hr/> 29.1

TIMEKEEPER SUMMARY

Timekeeper	Status	Hours	Rate	Value
Scott Davidson	Counsel	9.2	1290.00	11,868.00
Leia Shermohammed	Associate	19.9	745.00	14,825.50
Total		<hr/> 29.1		<hr/> \$26,693.50

08714 Purdue Pharma LP
240001 Retention And Fee Application
12/07/21

Invoice No. 10486455
Page 4

Task Summary - Fees

Task		Hours	Value
L120	Analysis/Strategy	9.2	10,325.16
L210	Pleadings	19.9	12,898.19
	Total Fees	<u>29.1</u>	<u>23,223.35</u>

KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:
King & Spalding LLP
P.O. Box 116133
Atlanta, GA 30368-6133

By Wire: SunTrust Bank
ABA: 061 000 104
SWIFT: SNTRUS3A
USD Account: 88003 12475
Account Name: King & Spalding

Purdue Pharma, LP (Document Matters)
Sent Electronically

Invoice No.	10486366
Invoice Date	12/03/21
Client No.	44444
Matter No.	795001

RE: 3rd Party Subpoena Response-Document/Discovery Services
Client Matter Reference: 20210003182

For questions, contact:
Rose Jones +1 404 215 5828

For Professional Services Rendered through 11/30/21:

Fees	\$	80,756.00
Less Tiered Discount		-5,652.92
Total this Invoice	\$	75,103.08

Payment is Due Upon Receipt

44444 Purdue Pharma, LP (Document Matters)
795001 3rd Party Subpoena Response-Document/Discovery
Services
12/03/21

Invoice No. 10486366
Page 2

PROFESSIONAL SERVICES

Date	Timekeeper	Task	Activity	Description	Hours
11/01/21	N Bass	L120	A101	Manage privilege review	1.5
11/01/21	R Jones	L120	A110	Participate in conference call with TCDI, Purdue and Wiggins regarding discovery strategy	0.5
11/02/21	N Bass	L120	A101	Manage privilege review	0.9
11/02/21	R Jones	L120	A110	Advise client on database structure	0.8
11/03/21	N Bass	L120	A101	Manage privilege review	1.8
11/04/21	N Bass	L120	A101	Manage privilege review	1.1
11/04/21	J Tucker	L320	A105	Manage review in connection with documents relating to the WDVA investigation	1.0
11/05/21	N Bass	L120	A101	Manage privilege review	0.4
11/05/21	R Jones	L120	A107	Participate in conference with TCDI, Cobra and Purdue regarding discovery strategy	0.5
11/05/21	J Tucker	L320	A105	Manage review in connection with custodial documents relating to the WDVA investigation	0.5
11/08/21	N Bass	L120	A101	Manage privilege review	1.6
11/08/21	K Burns	L320	A101	Coordinate document review and production workflows in response to ongoing case team and discovery requests	1.7
11/08/21	R Jones	L120	A110	Participate in conference with TCDI, Cobra and Purdue regarding discovery strategy	0.5
11/09/21	K Burns	L320	A101	Coordinate document review and production workflows in response to ongoing case team and discovery requests	1.2
11/09/21	R Jones	L120	A110	Participate in conference with R. Hoff and TCDI regarding review strategy	1.0
11/09/21	J Tucker	L320	A105	Manage review in connection with documents relating to the WDVA matter	0.4
11/10/21	N Bass	L120	A101	Manage privilege review	1.1
11/10/21	R Jones	L120	A110	Participate in conference call with TCDI, Cobra, T. Morrissey and R. Hoff regarding discovery strategy	0.4
11/10/21	J Tucker	L320	A104	Manage review in connection with	0.3

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services
 12/03/21

Invoice No. 10486366

Page 3

Date	Timekeeper	Task	Activity	Description	Hours
				custodial documents relating to the WDVA investigation	
11/12/21	N Bass	L120	A101	Manage privilege review	0.4
11/12/21	R Jones	L120	A110	Participate in conference call with TCDI, Cobra, T. Morrissey and R. Hoff regarding discovery strategy	0.4
11/14/21	R Jones	L120	A110	Prepare documents for production	0.4
11/15/21	N Bass	L120	A101	Manage privilege review	2.1
11/15/21	A Gibson	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	1.0
11/15/21	K Lynch	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	3.5
11/16/21	N Bass	L120	A101	Manage privilege review	0.9
11/16/21	K Burns	L320	A101	Coordinate document review and production workflows in response to ongoing case team and discovery requests	1.0
11/16/21	A Gibson	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation (1.9); quality control for privilege in connection with custodial documents relating to the WDVA investigation (5.9)	7.8
11/16/21	R Jones	L120	A110	Prepare documents for production	2.3
11/16/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	4.4
11/17/21	N Bass	L120	A101	Manage privilege review	1.7
11/17/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.5
11/17/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	8.2
11/17/21	R Jones	L120	A110	Prepare documents for production	3.1
11/17/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents	7.0

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services
 12/03/21

Invoice No. 10486366

Page 4

Date	Timekeeper	Task	Activity	Description	Hours
				relating to the WDVA investigation	
11/18/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.5
11/18/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	8.0
11/18/21	R Jones	L120	A110	Prepare documents for production	2.7
11/18/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	10.5
11/19/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	3.2
11/19/21	M Douglas	L320	A104	Quality control for privilege in connection with the WDVA review	5.1
11/19/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	9.4
11/19/21	R Jones	L120	A110	Prepare documents for production	3.4
11/19/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	5.2
11/19/21	E Smedley	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	1.1
11/19/21	E Smedley	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	0.7
11/19/21	E Smedley	L320	A104	Quality control for privilege in connection with the WDVA review	3.8
11/19/21	D Vandiver	L320	A104	Quality control for privilege in connection with the WDVA review	2.8
11/20/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.2
11/20/21	M Douglas	L320	A104	Quality control for privilege in connection with the WDVA review	2.1
11/20/21	C Harris	L320	A104	Review materials in connection with	4.6

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services
 12/03/21

Invoice No. 10486366

Page 5

Date	Timekeeper	Task	Activity	Description	Hours
				quality control for privilege in connection with custodial documents relating to the WDVA investigation (1.9); quality control for privilege in connection with custodial documents relating to the WDVA investigation (2.7)	
11/20/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	5.4
11/20/21	E Smedley	L320	A104	Quality control for privilege in connection with the WDVA review	3.6
11/20/21	H Wang	L320	A104	Quality control for privilege in connection with the WDVA review	4.5
11/21/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	2.0
11/21/21	C Harris	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	3.4
11/21/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	2.3
11/21/21	R Schreck	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation (0.5); quality control for privilege in connection with the WDVA review (2.2)	2.7
11/21/21	D Vandiver	L320	A104	Quality control for privilege in connection with the WDVA review	4.4
11/21/21	H Wang	L320	A104	Quality control for privilege in connection with the WDVA review	0.8
11/22/21	N Bass	L120	A101	Manage privilege review	1.1
11/22/21	K Burns	L320	A101	Coordinate document review and production workflows in response to ongoing case team and discovery requests	4.2
11/22/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.6
11/22/21	R Jones	L120	A110	Prepare documents for production	3.4

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services
 12/03/21

Invoice No. 10486366

Page 6

Date	Timekeeper	Task	Activity	Description	Hours
11/22/21	D Vandiver	L320	A104	Quality control for privilege in connection with the WDVA review	1.7
11/23/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	4.5
11/23/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	1.7
11/23/21	A Gibson	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	2.2
11/23/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	4.8
11/23/21	R Jones	L120	A110	Prepare documents for production	2.1
11/23/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	5.8
11/23/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation (3.3.); review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation (2.2)	5.5
11/23/21	D Vandiver	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	2.0
11/24/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.4
11/24/21	K Burns	L320	A101	Coordinate document review and production workflows in response to ongoing case team and discovery requests	1.0
11/24/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	9.1
11/24/21	K Lynch	L320	A104	Quality control for privilege in	4.0

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services
 12/03/21

Invoice No. 10486366

Page 7

Date	Timekeeper	Task	Activity	Description	Hours
				connection with custodial documents relating to the WDVA investigation	
11/24/21	D Vandiver	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation	1.5
11/25/21	D Vandiver	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	1.2
11/26/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.5
11/28/21	C Harris	L320	A104	Review materials in connection with quality control for privilege in connection with custodial documents relating to the WDVA investigation (2.4); quality control for privilege in connection with custodial documents relating to the WDVA investigation (4.8)	7.2
11/28/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	10.8
11/29/21	N Bass	L120	A101	Manage privilege review	1.3
11/29/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.9
11/29/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.6
11/29/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	8.1
11/29/21	C Harris	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	2.0
11/29/21	R Jones	L120	A110	Prepare documents for production	2.7
11/29/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	10.7
11/29/21	D Vandiver	L320	A104	Quality control for privilege in connection with custodial documents	4.6

44444 Purdue Pharma, LP (Document Matters)
 795001 3rd Party Subpoena Response-Document/Discovery
 Services

Invoice No. 10486366

Page 8

12/03/21

Date	Timekeeper	Task	Activity	Description	Hours
				relating to the WDVA investigation	
11/30/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.2
11/30/21	K Burns	L320	A104	Coordinate document review and production workflows in response to ongoing case team and discovery requests	0.2
11/30/21	A Gibson	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	8.2
11/30/21	C Harris	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	1.5
11/30/21	R Jones	L120	A110	Prepare documents for production	2.3
11/30/21	K Lynch	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	8.5
11/30/21	D Vandiver	L320	A104	Quality control for privilege in connection with custodial documents relating to the WDVA investigation	5.2
					<hr/> 286.6

TIMEKEEPER SUMMARY

Timekeeper	Status	Hours	Rate	Value
Rose Jones	Partner	26.5	500.00	13,250.00
John Tucker	Partner	2.2	500.00	1,100.00
Nicole Bass	Discovery Counsel	15.9	350.00	5,565.00
Kassi Burns	Discovery Counsel	25.1	350.00	8,785.00
Michael Douglas	Privilege Review Attorney	7.2	240.00	1,728.00
Reilly Schreck	Privilege Review Attorney	2.7	240.00	648.00
Eric Smedley	Privilege Review Attorney	9.2	240.00	2,208.00
David Vandiver	Privilege Review Attorney	23.4	240.00	5,616.00
Hao Wang	Privilege Review Attorney	5.3	240.00	1,272.00
Austin Gibson	Privilege Review Attorney	66.8	240.00	16,032.00
Chris Harris	Privilege Review Attorney	18.7	240.00	4,488.00
Kathleen Lynch	Privilege Review Attorney	83.6	240.00	20,064.00
Total		286.6		80,756.00

44444 Purdue Pharma, LP (Document Matters)
795001 3rd Party Subpoena Response-Document/Discovery
Services

Invoice No. 10486366

Page 9

12/03/21